Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tiagabine in the treatment of epilepsy - a clinical review with a guide for the prescribing physician
Autore:
Schmidt, D; Gram, L; Brodie, M; Kramer, G; Perucca, E; Kalviainen, R; Elger, CE;
Indirizzi:
Epilepsy Res Grp, D-14163 Berlin, Germany Epilepsy Res Grp Berlin Germany D-14163 Res Grp, D-14163 Berlin, Germany Univ Copenhagen, Hvidovre Hosp, Neurol Clin, DK-2650 Hvidovre, Denmark Univ Copenhagen Hvidovre Denmark DK-2650 Clin, DK-2650 Hvidovre, Denmark Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, GlasgowG11 6NT, Lanark, Scotland Univ Glasgow Glasgow Lanark Scotland G11 6NT gowG11 6NT, Lanark, Scotland Swiss Epilepsy Ctr, Zurich, Switzerland Swiss Epilepsy Ctr Zurich Switzerland Epilepsy Ctr, Zurich, Switzerland Univ Pavia, Dept Internal Med & Therapeut, Clin Pharmacol Unit, Pavia, Italy Univ Pavia Pavia Italy d & Therapeut, Clin Pharmacol Unit, Pavia, Italy Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland Kuopio Univ Hosp Kuopio Finland SF-70210 eurol, SF-70210 Kuopio, Finland Univ Bonn, Dept Epileptol, Bonn, Germany Univ Bonn Bonn GermanyUniv Bonn, Dept Epileptol, Bonn, Germany
Titolo Testata:
EPILEPSY RESEARCH
fascicolo: 3, volume: 41, anno: 2000,
pagine: 245 - 251
SICI:
0920-1211(200010)41:3<245:TITTOE>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMPLEX PARTIAL SEIZURES; PLACEBO-CONTROLLED TRIAL; ADD-ON THERAPY; PHARMACOKINETICS; TOLERABILITY; SINGLE; SAFETY;
Keywords:
tiagabine; antiepileptic drug; drug therapy; drug evaluation; prescribing guide; patient profile;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Schmidt, D Epilepsy Res Grp, Groethrasster 5, D-14163 Berlin, Germany Epilepsy Res Grp Groethrasster 5 Berlin Germany D-14163 ermany
Citazione:
D. Schmidt et al., "Tiagabine in the treatment of epilepsy - a clinical review with a guide for the prescribing physician", EPILEPSY R, 41(3), 2000, pp. 245-251

Abstract

Tiagabine is currently recommended mainly as add-on therapy in adults and children above 12 years with partial epilepsy not satisfactorily controlledwith other antiepileptic drugs. Based on available evidence and our clinical experience, tiagabine should be used preferably in patients sharing one or more of the following additional features, (i) a history of drug-inducedcutaneous adverse events; (ii) mild to moderate epilepsy allowing for a slow titration and gradual onset of anticonvulsant action over a few weeks; (iii) patients for whom it is particularly important to avoid a deterioration in cognitive performance; and, (iv) patients who failed to respond to previous treatment with sodium channel blocker agents as they may particularlybenefit from the introduction of tiagabine, due to its GABAergic mechanismof action. Tiagabine can also be used successfully in other patients with refractory partial epilepsy. Tiagabine is not indicated for patients with generalized or unclassified epilepsies and for patients with severely impaired liver function. (C) 2000 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 22:18:29